- Home
- XRTX vs BYAH Comparison
XRTX vs BYAH Comparison
Compare XRTX & BYAH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | XRTX | BYAH |
|---|---|---|
| Founded | 2011 | 2016 |
| Country | Canada | China |
| Employees | 3 | 41 |
| Industry | Pharmaceuticals and Biotechnology | Package Goods/Cosmetics |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.2M | 3.5M |
| IPO Year | 2018 | N/A |
Fundamental Metrics
Financial Performance| Metric | XRTX | BYAH |
|---|---|---|
| Price | $3.02 | $1.08 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 1.8M | 18.0K |
| Earning Date | 05-15-2026 | 03-02-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.35 | $0.05 |
| 52 Week High | $3.60 | $2.77 |
Technical Indicators
Market Signals| Indicator | XRTX | BYAH |
|---|---|---|
| Relative Strength Index (RSI) | 74.24 | 48.35 |
| Support Level | $0.52 | $0.93 |
| Resistance Level | N/A | $2.77 |
| Average True Range (ATR) | 0.37 | 0.06 |
| MACD | 0.06 | -0.00 |
| Stochastic Oscillator | 64.78 | 47.85 |
Price Performance
Historical ComparisonAbout XRTX XORTX Therapeutics Inc.
XORTX Therapeutics Inc is a clinical-stage pharmaceutical company focused on developing therapies to treat gout and progressive kidney disease modulated by aberrant purine and uric acid metabolism in orphan disease indications such as allopurinol-intolerant gout and autosomal dominant polycystic kidney disease, as well as more prevalent type 2 diabetic nephropathy and fatty liver disease. Its focus is on developing products to slow and/or reverse the progression of these diseases. The Company operates in one reportable operating segment: the development and commercialization of therapies to treat hyperuricemia-related diseases.
About BYAH Park Ha Biological Technology Co. Ltd. Ordinary Shares
Park Ha Biological Technology Co Ltd is engaged in developing its private skincare label, direct skincare products sales, and franchise alliances promotions. Its Park Ha brand focuses on providing solutions for problematic skin. The company's Operating Subsidiaries provide skincare and cosmetic products under its brand, Park Ha, in China. Its Operating Subsidiaries develop its proprietary beauty products and offer complementary after-sales beauty services in its physical stores.